Trevena Announces Presentations of OLINVYK™ Health Economic Models at AMCP 2021 Annual Meeting


CHESTERBROOK, PA – Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, announced two poster presentations at the AMCP 2021 Annual Meeting. The conference was held virtually from April 13th to 14th, 2021.

The posters highlight two health economic models developed for OLINVYK (oliceridine) injection, which estimate the budget impact of OLINVYK compared to IV morphine when used on-demand in a hospital setting for postoperative pain. A “Base Case” model assumes a broad patient population. A “High Risk” model limits the population to patients who are both elderly (≥ 65 years old) and obese (BMI ≥ 30 kg/m2), part of the Company’s initial core focus for launch. Both models were developed using AE incidence rates from the OLINVYK Phase 3 program and AE cost estimates from the published literature and claims data as referenced in the posters.

READ:  Ocugen Provides Business Update and First Quarter 2021 Financial Results

“Publishing these health economic models is the latest accomplishment in our ongoing launch of OLINVYK,” said Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer of Trevena, Inc. “These models form a critical component of the comprehensive product dossier for OLINVYK, and I am pleased to have this opportunity to share these compelling cost offset findings with key hospital stakeholders.”

One of the posters, “Budget Impact Analysis for Oliceridine in the Management of Moderate-to-Severe Acute Postoperative Pain,” was selected by the conference for a Gold Ribbon. This designation was awarded based on the same criteria used by Journal of Managed Care & Specialty Pharmacy to evaluate manuscripts and was only given to 20% of all submitted abstracts.

Poster Details

  1. Base Case Model: “Budget Impact Analysis for Oliceridine in the Management of Moderate-to Severe Acute Postoperative Pain” (Poster #U12)
    • OLINVYK is associated with a ~$230,000 decrease in total cost of care per 1,000 patients compared to IV morphine.
    • These cost savings are due to reduced AEs for OLINVYK-treated patients, as observed in the Phase 3 pivotal trials, and using a conservative, low-end estimate of AE costs based on government and published literature sources.
  2. High Risk Model: “Cost Effectiveness Analysis of Oliceridine Compared with Morphine in The Management of Postoperative Moderate to Severe Acute Pain in a High Risk Population” (Poster #U18)
    • OLINVYK is associated with savings of ~$364,000 in total cost of care per 1,000 patients, due to reduced AEs compared to IV morphine. The model estimates that the total cost of care associated with IV morphine would exceed $1.25M per 1,000 patients.
READ:  Nearly $60 Million to Those Allegedly Overcharged in Suboxone Film Scheme

All posters can be found at While the cost savings in these health economic models cannot be guaranteed, the Company states that they are based on generally accepted methodology, and pharmacy and therapeutics committees typically review health economic models when making drug formulary decisions.

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.

Disclosure: This site contains affiliate links to products, identified by the Affiliate Disclosure icon. MyChesCo may receive a commission for purchases made through these links.

Buy Us a Cup of Coffee
Notify of
Inline Feedbacks
View all comments